LIF polyclonal, anti-human, mouse, rat
€484.00
In stock
SKU
254447
Protein Family: Enzymes
Pathway and Disease: Signaling Molecules and Interaction
Description:
LIF is a pleiotropic cytokine with roles in several different systems. It is involved in the induction of hematopoietic differentiation in normal and myeloid leukemia cells, induction of neuronal cell differentiation, regulator of mesenchymal to epithelial conversion during kidney development, and may also have a role in immune tolerance at the maternal-fetal interface. LIF was initially recognized by its ability to induce terminal differentiation of myeloid leukemic cells. It is a member of the IL-6 cytokine superfamily and can be highly glycosylated. LIF signaling is transduced through the LIF-R/gp130 receptor complex, leading to the phosphorylation and activation of the JAK/STAT pathway. Recent evidence shows that LIF inhibits cardiomyogenesis in embryonic stem cells via STAT3 activation.
Alternate Names: Leukemia inhibitory factor, CDF, DIA, HILDA, MLPLI
Application Notes: E: 1:500-1:1,000; WB: 1:100-1:500
Accession No.: NP_002300
Antigen: KLH-conjugated synthetic peptide encompassing a sequence within human LIF.
Format: Each vial contains 0.1 ml IgG in PBS pH 7.4 with 0.02% sodium azide. Antibody was purified by immunogen affinity chromatography.
Storage:
Store at -20°C. Minimize freeze-thaw cycles. Product is guaranteed one year from the date of shipment.
Pathway and Disease: Signaling Molecules and Interaction
Description:
LIF is a pleiotropic cytokine with roles in several different systems. It is involved in the induction of hematopoietic differentiation in normal and myeloid leukemia cells, induction of neuronal cell differentiation, regulator of mesenchymal to epithelial conversion during kidney development, and may also have a role in immune tolerance at the maternal-fetal interface. LIF was initially recognized by its ability to induce terminal differentiation of myeloid leukemic cells. It is a member of the IL-6 cytokine superfamily and can be highly glycosylated. LIF signaling is transduced through the LIF-R/gp130 receptor complex, leading to the phosphorylation and activation of the JAK/STAT pathway. Recent evidence shows that LIF inhibits cardiomyogenesis in embryonic stem cells via STAT3 activation.
Alternate Names: Leukemia inhibitory factor, CDF, DIA, HILDA, MLPLI
Application Notes: E: 1:500-1:1,000; WB: 1:100-1:500
Accession No.: NP_002300
Antigen: KLH-conjugated synthetic peptide encompassing a sequence within human LIF.
Format: Each vial contains 0.1 ml IgG in PBS pH 7.4 with 0.02% sodium azide. Antibody was purified by immunogen affinity chromatography.
Storage:
Store at -20°C. Minimize freeze-thaw cycles. Product is guaranteed one year from the date of shipment.
| Is Featured? | No |
|---|
Write Your Own Review